Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14404929 | 1.00 | LMNA (0.51) | LMNARNPEPFOLH1MAPK1ALDH1A1 | |
| SCHEMBL3869335 | 1.00 | LMNA (0.51) | LMNARNPEPFOLH1MAPK1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11125960 | 0.98 | LMNA (0.50) | LMNARNPEPFOLH1MAPK1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28941784 | 0.98 | LMNA (0.50) | LMNARNPEPFOLH1MAPK1ALDH1A1 | |
| Acrylic Acid SCHEMBL1536190 | 0.90 | LMNA (0.44) | LMNARNPEPFOLH1MAPK1ALDH1A1 | |
| SCHEMBL2118366 | 0.85 | RNPEP (0.46) | LMNARNPEPFOLH1MAPK1ALDH1A1 | |
| SCHEMBL2118362 | 0.85 | RNPEP (0.46) | LMNARNPEPFOLH1MAPK1ALDH1A1 | |
| SCHEMBL10296118 | 0.85 | LMNA (0.42) | LMNARNPEPFOLH1MAPK1ALDH1A1 | |
| SCHEMBL5179354 | 0.84 | RNPEP (0.48) | LMNARNPEPFOLH1MAPK1ALDH1A1 | |
| SCHEMBL149342 | 0.84 | RNPEP (0.48) | LMNARNPEPFOLH1MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250268982-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND/OR PROPHYLAXIS OF PROTEINOPATHIES | REGAIN THERAPEUTICS SWEDEN AB (SE) | 2025-08-28 | — | — | US | claimed |
| EP-4347628-A2 | COMPOSITIONS AND METHODS FOR TREATMENT AND/OR PROPHYLAXIS OF PROTEINOPATHIES | Regain Therapeutics Sweden AB (SE) | 2024-04-10 | — | — | EP | claimed |
| US-20220380425-A1 | ANGPTL3 BASED VACCINE FOR THE TREATMENT OF LIVER DISEASE | CADILA HEALTHCARE LIMITED (IN) | 2022-12-01 | — | — | US | claimed |
| WO-2022248650-A2 | COMPOSITIONS AND METHODS FOR TREATMENT AND/OR PROPHYLAXIS OF PROTEINOPATHIES | REGAIN THERAPEUTICS SWEDEN AB (SE) | 2022-12-01 | — | — | WO | claimed |
| EP-3993820-A1 | ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 | Cadila Healthcare Limited (IN) | 2022-05-11 | — | — | EP | claimed |
| CN-112334470-A | Crystalline salts of 5-methyl- (6S) -tetrahydrofolic acid and amino acid ethyl ester | 默克专利股份有限公司 | 2021-02-05 | — | — | CN | claimed |
| US-20250268982-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND/OR PROPHYLAXIS OF PROTEINOPATHIES | REGAIN THERAPEUTICS SWEDEN AB (SE) | 2025-08-28 | — | — | US | disclosed |
| EP-4347628-A2 | COMPOSITIONS AND METHODS FOR TREATMENT AND/OR PROPHYLAXIS OF PROTEINOPATHIES | Regain Therapeutics Sweden AB (SE) | 2024-04-10 | — | — | EP | disclosed |
| CN-117320685-A | Composition for skin protection comprising an antimicrobial agent and a (bio) -alkanediol | 西姆莱斯股份公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-116685300-A | Composition comprising one or more (bio) -alkanediols with an antioxidant | 西姆莱斯股份公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-116234802-A | Quinoline CGAS antagonist compounds | 免疫传感器治疗股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-116075299-A | Nutritional formulations | 株式会社大塚制药工场 | 2023-05-05 | — | — | CN | disclosed |
| WO-2022248650-A2 | COMPOSITIONS AND METHODS FOR TREATMENT AND/OR PROPHYLAXIS OF PROTEINOPATHIES | REGAIN THERAPEUTICS SWEDEN AB (SE) | 2022-12-01 | — | — | WO | disclosed |
| WO-2005032578-A1 | THERAPEUTIC METHOD | MONASH UNIVERSITY (AU) | 2005-04-14 | — | — | WO | disclosed |
| WO-2004028475-A2 | GLYCOSYLCERAMIDE ANALOGUES | BIOMIRA, INC. (CA) | 2004-04-08 | — | — | WO | disclosed |
| EP-0894010-A2 | DENATURANTS FOR SYMPATHOMIMETIC AMINE SALTS | Warner-Lambert Company LLC (US) | 1999-02-03 | — | — | EP | disclosed |
| WO-1997037689-A2 | DENATURANTS FOR SYMPATHOMIMETIC AMINE SALTS | WARNER-LAMBERT COMPANY (US) | 1997-10-16 | — | — | WO | disclosed |
| CN-1150419-A | Novel farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing same | RHONE POULENC RORER SA (FR) | 1997-05-21 | — | — | CN | disclosed |
| EP-0047879-B1 | PROCESS FOR PREPARING MODIFIED PROTEIN COMPOSITIONS | TERUMO CORPORATION (JP) | 1984-05-16 | — | — | EP | disclosed |
| EP-0047879-A1 | Process for preparing modified protein compositions | TERUMO CORPORATION (JP) | 1982-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380425-A1 | ANGPTL3 BASED VACCINE FOR THE TREATMENT OF LIVER DISEASE | HDGFL3, PCSK9, TEK | LMNA 2098/4885RNPEP 818/4885FOLH1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.